AHA 2024 - The BPROAD study investigated whether intensive SBP reduction (<120 mmHg) vs. standard SBP reduction (<140 mmHg) offers greater protection for CV outcomes in patients with T2DM. Discussant Shawna Nesbitt reviews the results.
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Shawna Nesbitt, MD is the John C. Vanatta III Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024
Recommended
Details
Presenters
Overview
AHA 2024 - The BPROAD study investigated whether intensive SBP reduction (<120 mmHg) vs. standard SBP reduction (<140 mmHg) offers greater protection for CV outcomes in patients with T2DM. Discussant Shawna Nesbitt reviews the results.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Shawna Nesbitt, MD is the John C. Vanatta III Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
0.50 credits
<p>IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
Project Oncology®
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
<p>HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)</p>
CME/CE
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
1.00 credits
<p>Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?